AR118983A1 - Antagonistas cíclicos del receptor b2 de bradiquinina - Google Patents
Antagonistas cíclicos del receptor b2 de bradiquininaInfo
- Publication number
- AR118983A1 AR118983A1 ARP200101444A ARP200101444A AR118983A1 AR 118983 A1 AR118983 A1 AR 118983A1 AR P200101444 A ARP200101444 A AR P200101444A AR P200101444 A ARP200101444 A AR P200101444A AR 118983 A1 AR118983 A1 AR 118983A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- substituted
- hydrogen atom
- halogen atom
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente se refiere a un compuesto de acuerdo con la formula general (1), que actúa como un antagonista del receptor de bradiquinina (BK) B2; a una composición farmacéutica que contiene uno o más compuestos de la presente; a una preparación de combinación que contiene al menos un compuesto de la misma y al menos otro principio farmacéuticamente activo adicional; y a los usos de dicho(s) compuesto(s), incluido el uso como medicamento. Reivindicación 1: Un compuesto de fórmula general (1), o una de sus sales, en donde A representa un grupo seleccionado del grupo de fórmulas (2); A¹ es N o CH; A² es N o C-RA²; A³ es N o C-RA³; A⁴ es NH, O ó S; A⁵ es N-RA⁵; RA¹ representa un átomo de hidrógeno o un grupo metilo; cada uno de RA² y RA³, independientemente entre sí, representa un átomo de hidrógeno, un átomo de halógeno, OH, CN, NH₂; alquilo C₁₋₃, que puede estar sustituido con uno o más, grupo(s), idénticos o diferentes, seleccionados entre un átomo de halógeno, OH, =O y NH₂; alcoxi C₁₋₃, que puede estar sustituido con uno o más grupo(s), idénticos o diferentes, seleccionados entre un átomo de halógeno, OH, =O y NH₂; alcoxialquilo C₂₋₅, que puede estar sustituido con uno o más, grupo(s), idénticos o diferentes, seleccionados entre un átomo de halógeno, OH, =O y NH₂; C(O)NRA⁶RA⁷; o NRA⁶RA⁷; RA⁵, RA⁶ y RA⁷, cada uno independientemente entre sí, representa un átomo de hidrógeno o un grupo alquilo C₁₋₃, que puede estar sustituido con uno o más, grupo(s), idénticos o diferentes, seleccionados entre un átomo de halógeno, OH, =O y NH₂; R representa un átomo de hidrógeno o un átomo de deuterio; B representa un grupo heterocicloalquilo, saturado o parcialmente insaturado, de 5 ó 6 miembros, el cual puede sustituirse por uno o más, iguales o diferentes, grupo(s) seleccionados entre =O, un átomo de halógeno, RB¹, ORB² y NH₂; RB¹ representa un átomo de hidrógeno o RB²; RB² representa un alquilo C₁₋₃, haloalquilo C₁₋₃, hidroxialquilo C₁₋₃ o un grupo heteroalquilo C₁₋₃; R representa un átomo de hidrógeno o G; G representa un grupo alquilo C₁₋₆, en el cual de 1 a 5 átomos de H pueden, en cada ocasión independientemente, reemplazarse por =O, un átomo de halógeno, ORG¹ o un anillo heterocíclico de 5 miembros el cual puede sustituirse opcionalmente con uno o dos RB²; RG¹ representa un átomo de hidrógeno, alquilo C₁₋₃, haloalquilo C₁₋₃, hidroxialquilo C₁₋₃ o un grupo heteroalquilo C₁₋₃; y n indica el número 0 ó 1.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19176229 | 2019-05-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR118983A1 true AR118983A1 (es) | 2021-11-17 |
Family
ID=66668714
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP200101444A AR118983A1 (es) | 2019-05-23 | 2020-05-21 | Antagonistas cíclicos del receptor b2 de bradiquinina |
Country Status (13)
Country | Link |
---|---|
US (1) | US20220289730A1 (es) |
EP (1) | EP3956326B1 (es) |
JP (1) | JP7459235B2 (es) |
CN (1) | CN113906020B (es) |
AR (1) | AR118983A1 (es) |
AU (1) | AU2020277697B2 (es) |
CA (1) | CA3139228A1 (es) |
ES (1) | ES2958457T3 (es) |
MX (1) | MX2021014287A (es) |
PL (1) | PL3956326T3 (es) |
TW (1) | TWI827846B (es) |
UY (1) | UY38707A (es) |
WO (1) | WO2020234480A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY38706A (es) * | 2019-05-23 | 2020-12-31 | Pharvaris Gmbh | Antagonistas cíclicos del receptor b2 de bradiquinina |
AR118983A1 (es) | 2019-05-23 | 2021-11-17 | Pharvaris Gmbh | Antagonistas cíclicos del receptor b2 de bradiquinina |
TW202345810A (zh) * | 2022-03-25 | 2023-12-01 | 瑞士商帕法瑞斯有限責任公司 | 包含緩激肽b2受體拮抗劑之固態延長釋放組成物 |
WO2023180575A1 (en) * | 2022-03-25 | 2023-09-28 | Pharvaris Gmbh | Solid composition comprising solubilised bradykinin b2-receptor antagonists |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU680870B2 (en) | 1993-04-28 | 1997-08-14 | Astellas Pharma Inc. | New heterocyclic compounds |
WO1996013485A1 (en) | 1994-10-27 | 1996-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Pyridopyrimidones, quinolines and fused n-heretocycles as bradykinin antagonists |
FR2737892B1 (fr) | 1995-08-17 | 1997-10-24 | Fournier Ind & Sante | Nouveaux composes de benzenesulfonamide, procede de preparation et utilisation en therapeutique |
GB9602029D0 (en) | 1996-02-01 | 1996-04-03 | Fujisawa Pharmaceutical Co | New heterocyclic compounds |
DE19609827A1 (de) | 1996-03-13 | 1997-09-18 | Hoechst Ag | Aminoalkyl- und Acylaminoalkylether, Verfahren zu deren Herstellung und ihre Verwendung als Bradykinin-Rezeptorantagonisten |
DE19610784A1 (de) | 1996-03-19 | 1997-09-25 | Hoechst Ag | Fluoralkyl- und Fluoralkoxysubstituierte heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung |
DE19612067A1 (de) | 1996-03-27 | 1997-10-02 | Hoechst Ag | Verwendung von Bradykinin-Antagonisten zur Herstellung von Arzneimitteln zur Behandlung von chronisch fibrogenetischen Lebererkrankungen und akuten Lebererkrankungen |
AUPN952696A0 (en) | 1996-04-29 | 1996-05-23 | Fujisawa Pharmaceutical Co., Ltd. | New heterocyclic compounds |
DE19712960A1 (de) | 1997-03-27 | 1998-10-01 | Hoechst Ag | Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten |
AU4335299A (en) | 1998-06-08 | 1999-12-30 | Advanced Medicine, Inc. | Bradykinin antagonists |
BR9914785A (pt) | 1998-10-21 | 2001-07-03 | Fujisawa Pharmaceutical Co | Formavìtrea de 8-[3-[n-[(e)-3-(6-acetamidopiridin-3-il) acriloilglicil]-n-metilamino]-2,6-diclorobenziloxi)-2- metilquinolina, processo para sua preparação, composição farmacêutica compreendendo a mesma, agente de prevenção, seu métodos e uso |
FR2790260B1 (fr) * | 1999-02-26 | 2001-05-04 | Fournier Ind & Sante | Nouveaux composes de n-(benzenesulfonamide), procede de preparation et utilisation en therapeutique |
WO2000059886A2 (en) * | 1999-04-02 | 2000-10-12 | Neurogen Corporation | Benzimidazole abd imidazolophyridine derivaties, their preparation and their use as selective modulators of bradykinin b2 (=bk-2) receptors |
GB9913079D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
WO2001056995A1 (en) | 2000-01-18 | 2001-08-09 | Nuerogen Corporation | Substituted imidazoles as selective modulators of bradykinin b2 receptors |
CA2364178C (en) | 2000-12-05 | 2006-01-10 | Yasuhiro Katsu | N-benzenesulfonyl l-proline compounds as bradykinin antagonists |
AU2003226188A1 (en) | 2002-04-10 | 2003-10-27 | Ortho-Mcneil Pharmaceutical, Inc. | Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators |
ITMI20021247A1 (it) | 2002-06-07 | 2003-12-09 | Menarini Ricerche Spa | Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche |
ITMI20041963A1 (it) * | 2004-10-15 | 2005-01-15 | Luso Farmaco Inst | "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche" |
EP1741444A1 (en) | 2005-07-05 | 2007-01-10 | Jerini AG | Kinin antagonists for treating bladder dysfunction |
TWI407960B (zh) * | 2007-03-23 | 2013-09-11 | Jerini Ag | 小分子緩激肽b2受體調節劑 |
AR073304A1 (es) | 2008-09-22 | 2010-10-28 | Jerini Ag | Moduladores del receptor de bradiquinina b2 de molecula pequena |
CN105228623A (zh) * | 2013-03-14 | 2016-01-06 | 夏尔人类遗传性治疗公司 | 治疗b2-缓激肽受体介导的血管性水肿的方法 |
MA50804B1 (fr) | 2017-11-24 | 2022-05-31 | Pharvaris Netherlands B V | Nouveaux antagonistes des récepteurs de bradykinine b2 |
AR118983A1 (es) | 2019-05-23 | 2021-11-17 | Pharvaris Gmbh | Antagonistas cíclicos del receptor b2 de bradiquinina |
-
2020
- 2020-05-21 AR ARP200101444A patent/AR118983A1/es unknown
- 2020-05-21 UY UY0001038707A patent/UY38707A/es unknown
- 2020-05-22 TW TW109117161A patent/TWI827846B/zh active
- 2020-05-25 EP EP20732117.5A patent/EP3956326B1/en active Active
- 2020-05-25 ES ES20732117T patent/ES2958457T3/es active Active
- 2020-05-25 MX MX2021014287A patent/MX2021014287A/es unknown
- 2020-05-25 CN CN202080037896.4A patent/CN113906020B/zh active Active
- 2020-05-25 JP JP2022516260A patent/JP7459235B2/ja active Active
- 2020-05-25 PL PL20732117.5T patent/PL3956326T3/pl unknown
- 2020-05-25 CA CA3139228A patent/CA3139228A1/en active Pending
- 2020-05-25 US US17/612,951 patent/US20220289730A1/en active Pending
- 2020-05-25 WO PCT/EP2020/064379 patent/WO2020234480A1/en unknown
- 2020-05-25 AU AU2020277697A patent/AU2020277697B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3956326B1 (en) | 2023-06-28 |
ES2958457T3 (es) | 2024-02-08 |
CA3139228A1 (en) | 2020-11-26 |
JP7459235B2 (ja) | 2024-04-01 |
CN113906020A (zh) | 2022-01-07 |
AU2020277697A1 (en) | 2021-11-18 |
MX2021014287A (es) | 2022-01-06 |
EP3956326C0 (en) | 2023-06-28 |
PL3956326T3 (pl) | 2024-01-22 |
UY38707A (es) | 2020-12-31 |
US20220289730A1 (en) | 2022-09-15 |
CN113906020B (zh) | 2024-03-12 |
JP2022533487A (ja) | 2022-07-22 |
AU2020277697B2 (en) | 2023-08-24 |
TWI827846B (zh) | 2024-01-01 |
EP3956326A1 (en) | 2022-02-23 |
WO2020234480A1 (en) | 2020-11-26 |
TW202110833A (zh) | 2021-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR118983A1 (es) | Antagonistas cíclicos del receptor b2 de bradiquinina | |
AR113839A1 (es) | Antagonistas del receptor b2 de bradiquinina | |
UY37795A (es) | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 | |
UY28578A1 (es) | Derivados de amida | |
UY29301A1 (es) | Derivados amida | |
PE20151437A1 (es) | Moduladores de receptores nmda de espiro-lactama y sus usos | |
AR084849A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
AR065015A1 (es) | Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer | |
PE20160548A1 (es) | Sulfonamidas como moduladores de canales de sodio | |
AR067475A1 (es) | Antagonistas no basico s del receptor de la hormona concentradora de melanina 1 | |
EA200970510A1 (ru) | Гетеромоноциклическое соединение и его применение | |
CO6270361A2 (es) | Compuestos de piperidina tipo quinoxalina sustituida y uso de los mismos | |
CR10922A (es) | Derivados de indol como antagonistas receptores de s1p1 | |
AR049696A1 (es) | Derivados de indol | |
AR056893A1 (es) | Compuestos heterociclicos fusionados y no fusionados, antagonistas de receptores mineralocorticoides | |
AR058073A1 (es) | Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos | |
UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
AR079486A1 (es) | Compuestos heterociclicos nitrogenados de oxima, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades proliferativas. | |
AR089781A1 (es) | Fluorometil-5,6-dihidro-4h-[1,3]oxazinas | |
PE20090620A1 (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen | |
BR112015015275A8 (pt) | composto heterocíclico substituído por halogênio, antagonista do receptor de lpa, composição farmacêutica e uso | |
PE20240930A1 (es) | Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton | |
AR054102A1 (es) | Derivados de fenil-piperazina-metanona. procesos de obtencion y composiciones farmaceuticas | |
CL2020001817A1 (es) | Moduladores del receptor c5a | |
ECSP088257A (es) | Derivados de amida |